And for full clarity to those not on the call, here is the transcript on the topic of FDA staff.
We're a well funded company that's retaining all its revenue benefits and maximizing our cash flow. But what's really important here is that there's been some conjecture in the market in recent times around what the dodge, the Department of Government Efficiency, which is, which is really active in the US at the moment.
What effect has that had on the US fda? What effect is that potentially having on people who have their applications pending? And so I'm delighted to inform that we are on track for our clearance and we haven't changed our expectation of approval in late March and early April.
We know that there's been quite a lot of conjecture in the market around layoffs within the fda and it's been super interesting to watch from afar and that is that we saw, you know, some two and a half thousand temporary staff the FDA let go and that was reported to the market and I think caused a little bit of uncertainty as to, you know, does that affect us? Will it affect, you know, the length of time it takes to get approved in that market? Interestingly, what we saw reported yesterday was that a very large number of those staff that were Let go not 10 days ago had now been re employed by the FDA.
And so, you know, that's created some confusion, but it's given great comfort that these approval processes for medical devices such as ours are on track. Our interactions with the FDA have remained positive. And it's really important to note that our lead reviewer remains the same.
And so we are still on target for that end of March, early April, FDA clearance or notification from them. So we're excited about that scenario. What I think has been really exciting also for the company and investors has been a very, very strong rewrite of the company.
(20min delay)